Author: Wysocki, Jan; Schulze, Arndt; Batlle, Daniel
Title: Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System Document date: 2019_12_17
ID: 0vozochc_1
Snippet: Angiotensin Converting Enzyme-2 (ACE2) is a monocarboxypeptidase that degrades several substrates, of which Ang II is most relevant because of the extensive biologic effects of this peptide and the attendant formation of Ang (1-7), which has actions generally opposite to those of Ang II [1] [2] [3] [4] [5] [6] [7] [8] [9] . ACE2 protein in its full-length form is an 805 amino-acid (AA) type-I transmembrane protein (110-120 kDa) that contains an e.....
Document: Angiotensin Converting Enzyme-2 (ACE2) is a monocarboxypeptidase that degrades several substrates, of which Ang II is most relevant because of the extensive biologic effects of this peptide and the attendant formation of Ang (1-7), which has actions generally opposite to those of Ang II [1] [2] [3] [4] [5] [6] [7] [8] [9] . ACE2 protein in its full-length form is an 805 amino-acid (AA) type-I transmembrane protein (110-120 kDa) that contains an extracellular domain (AA 1-740), a transmembrane region (AA 741-768), and an intracellular tail (769-805) [10, 11] . The extracellular part of ACE2 (1-740 AA), here referred as "native" ACE2, contains the catalytic domain and is fully catalytically active. In our previous studies, the administration of native rACE2 (1-740 AA) resulted in a marked increase in circulating ACE2 activity, but neither kidney nor urinary ACE2 activity increased [6, 12, 13] .
Search related documents:
Co phrase search for related documents- AA type and amino acid AA type: 1
- AA type and previous study: 1
- AA type and transmembrane protein: 1
- amino acid and catalytic domain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- amino acid and extracellular domain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- amino acid and intracellular tail: 1
- amino acid and length form: 1, 2
- amino acid and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- amino acid and transmembrane protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- amino acid and transmembrane region: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- catalytic domain and extracellular domain: 1, 2, 3, 4, 5, 6, 7
- catalytic domain and length form: 1, 2
- catalytic domain and previous study: 1
- catalytic domain and transmembrane protein: 1, 2, 3, 4, 5, 6, 7
- catalytic domain and transmembrane region: 1, 2, 3, 4, 5
- extracellular domain and intracellular tail: 1, 2
- extracellular domain and previous study: 1
- extracellular domain and transmembrane protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- extracellular domain and transmembrane region: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date